XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. At September 30, 2022 and December 31, 2021, the carrying amount of cash and cash equivalents, accounts receivable, other current assets, other assets, accounts payable, and accrued and other current liabilities approximated their estimated fair value due to their relatively short maturities. The carrying amounts of borrowings under a certain credit agreement approximate fair value as interest rates on these instruments are variable and approximate current market rates. The following table sets forth the Company’s financial instruments that were measured at fair value by level within the fair value hierarchy on a recurring basis as of the dates indicated (in thousands):
As of September 30, 2022
Balance Sheet LocationTotalLevel 1Level 2Level 3
Financial Assets:
Unrestricted Balances
Money market funds(1)
Cash and cash equivalents$723,394 $723,394 $— $— 
Total financial assets$723,394 $723,394 $— $— 
As of December 31, 2021
Balance Sheet LocationTotalLevel 1Level 2Level 3
Financial Assets:
Unrestricted Balances
Money market funds(1)
Cash and cash equivalents$1,070,979 $1,070,979 $— $— 
Marketable equity securitiesPrepaid expenses and other current assets$2,532 $2,532 $— $— 
Restricted Balances
Money market fundsRestricted cash equivalents$1,050,000 $1,050,000 — — 
Total financial assets$2,123,511 $2,123,511 $— $— 
(1) Includes balances in money market deposit accounts of $535.4 million and $921.0 million as of September 30, 2022 and December 31, 2021, respectively.
Non-Marketable Equity Securities Measured at Net Asset Value
The Company held equity interests in certain private equity funds of $20.6 million and $3.2 million as of September 30, 2022 and December 31, 2021, respectively, which are measured using the net asset value practical expedient. Under the net asset value practical expedient, the Company records investments based on the proportionate share of the underlying funds’ net asset value as of the Company's reporting date. These investments are included in other assets in the Company’s condensed consolidated balance sheets.
These funds vary in investment strategies and generally have an initial term of 7 to 10 years, which may be extended for 2 to 3 additional years with the applicable approval. These investments are subject to certain restrictions regarding transfers and withdrawals and generally cannot be redeemed with the funds. Distributions from the funds will be received as the underlying investments are liquidated. The Company’s maximum exposure to loss is limited to the carrying value of these investments of $20.6 million and the unfunded commitments of $36.1 million as of September 30, 2022.
During the three and nine months ended September 30, 2022, the Company made total capital contributions of $0.1 million and $18.6 million related to these investments. The Company recorded an unrealized gain of $0.8 million related to these investments in other income, net in the Company’s condensed consolidated statement of operations for the nine months ended September 30, 2022. The unrealized loss of these investments for the three months ended September 30, 2022 was immaterial. The Company had no such investments in 2021.
Non-Marketable Equity Securities Measured at Fair Value on a Non-Recurring Basis
During the second quarter of 2022, the Company purchased certain non-marketable equity securities for total proceeds of $38.0 million. Non-marketable equity securities are investments in privately held companies without readily determinable fair values. The Company elected the measurement alternative to account for these investments. Under the measurement alternative, the carrying value of the non-marketable equity securities are adjusted based on price changes from observable transactions of identical or similar securities of the same issuer or for impairment. Any changes in carrying value are recorded within other income (expense), net in the Company's condensed consolidated statement of operations. There was no change in the carrying value of the non-marketable equity securities since their acquisitions. These investments are included in other assets in the Company’s condensed consolidated balance sheets. The Company had no such investments in 2021.